Keywords: adrenoceptor adverse events antimuscarinics overactive bladder therapeutic efficacy a b s t r a c t Objective: Mirabegron, a b 3 -adrenoceptor agonist, has been shown to be effective and safe in the treatment of overactive bladder (OAB). The aim of this study was to assess the efficacy and safety of mirabegron (50 mg) versus placebo in Taiwanese patients with OAB. Materials and patients: This was a multicenter, randomized, double-blind, parallel-group, placebo-and active-controlled trial conducted at 12 sites in Taiwan. Patients were randomized in a 1:1:1 ratio to receive placebo, mirabegron (50 mg), or tolterodine extended release (4 mg) orally once daily for 12 weeks. The primary efficacy end point was the change in the mean number of micturitions per 24 hours from baseline to the final visit. Secondary end points were volume voided, and the number of urgency, urinary incontinence, urge incontinence, and nocturia episodes per 24 hours; in addition, the King's Health Questionnaire (KHQ) was administered to assess effects on quality of life. Results: A total of 218 patients were included in the full analysis set (68 in the placebo group; 76 in the mirabegron group; and 74 in the tolterodine group). The adjusted mean difference between the mirabegron and placebo groups for the change in mean number of micturitions per 24 hours was À1.42 (p ¼ 0.004). The adjusted mean difference between the mirabegron and placebo groups with regard to the change in volume voided per micturition was 16.7 mL (p ¼ 0.013). However, the mirabegron group did not show statistically significant superiority to the placebo group in the other efficacy variables. There was also no statistically significant difference between mirabegron and placebo in any KHQ domain score. The incidence of treatment-emergent adverse events in the mirabegron group was low and similar to that in the placebo group. 
Introduction
Overactive bladder (OAB) syndrome is characterized by urinary urgency with or without urgency incontinence, 1 which affects > 400 million people worldwide. 2 Epidemiology studies have also revealed that OAB affects 12e16% of the adult population across Europe, the USA, and Japan. 3e5 Antimuscarinics have been considered the first-line pharmacotherapy for OAB. 6e8 However, a high proportion of patients discontinue antimuscarinic therapy due to suboptimal efficacy or intolerable adverse events (AEs) with < 25% remaining on treatment at 1 year. 9, 10 There is therefore an urgent need to develop new drugs for OAB that do not have the adverse effects of antimuscarinic agents.
The b 3 -adrenergic receptors have been known to promote urine storage in the bladder by inducing detrusor relaxation in animal and human bladders. 11e13 The b 3 -adrenoceptor is the predominant b-receptor subtype in the human urinary bladder, representing 97% of total b-adrenoceptor messenger RNA expression in the human bladder. 14 The b 3 -adrenoceptor agonists relax the detrusor smooth muscle during the bladder storage phase and increase bladder capacity. 15 Unlike the mechanism of antimuscarinic agents, b 3 -adrenoceptor agonists increase bladder capacity without a change in micturition pressure, residual volume, or voiding contraction. 16e18 Mirabegron, a b 3 -adrenoceptor agonist, is a first-in-class drug for the treatment of OAB. 19 Mirabegron demonstrated significant dose-dependent improvements in key OAB symptoms in one phase II study. 20 Pooled safety data indicated that mirabegron may be a valuable treatment option for patients with OAB as the incidence of dry mouth, the chief cause of discontinuation of antimuscarinic agents, was lower than with the use of an active comparator, tolterodine extended release (ER; 4 mg). 21 Although recent phase III trials have confirmed the efficacy and safety of mirabegron in treatment of OAB in European, Australian, North American, and Japanese populations, 22e25 the therapeutic efficacy and safety had not been demonstrated in Taiwanese people. This phase III study aims to assess the efficacy of mirabegron [50 mg once daily (qd)] against placebo in Taiwanese people with symptoms of OAB. The efficacy and safety of mirabegron were also compared with tolterodine sustained release (SR; 4 mg qd), the reference drug, without a noninferiority test. We also compared the results of this study with clinical trials in other regions of the world.
Materials and patients

Study design and participants
This 12-week multinational and multicenter, randomized, double-blind, parallel-group, placebo-and active-controlled trial was conducted at 12 sites in Taiwan. The study population consisted of men and women over the age of 18 years with symptoms of OAB for > 3 months. The study-drug-administration period consists of 14 weeks in total including 2 weeks for administration of the placebo for the run-in period and 12 weeks for administration of the study drug for the treatment period (Fig. 1) . Patients who met the inclusion criteria and did not violate the exclusion criteria were randomized to receive the study drug [mirabegron (50 mg), tolterodine (4 mg), or placebo] orally, once a day after breakfast, for 12 weeks.
The patients were provisionally enrolled for randomization. The inclusion and exclusion criteria are listed in Appendix 1. Medications that might affect lower urinary tract function were restricted, such as a1-adrenoceptor antagonists, medication for diabetes insipidus, antidepressants, 5a-reductase inhibitors, injection of capsaicin or resiniferatoxin into the bladder, or injection of botulinum toxin into bladder muscles. After having fulfilled all selection criteria at the end of the placebo run-in period (Visit 2), patients were randomized to one of the three treatment groups in a 1:1:1 ratio to receive placebo, mirabegron (50 mg), or tolterodine ER (4 mg) orally once daily for 12 weeks, using a computer-generated randomization list. During the placebo run-in period, patients were blinded to the identity of the study drug, and during the doubleblind treatment, both patients and investigators were blinded to the identity of the randomized drug assignment.
All patients provided written informed consent. The study was approved by the Institutional Review Board of each study site and conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice, International Conference on Harmonization guidelines, and all applicable laws and regulations. a Adjusted change from baseline results are generated from the analysis of covariance model with the treatment group as a fixed factor and baseline as a covariate.
Efficacy end points
The primary efficacy end point was the change in the mean number of micturitions per 24 hours from baseline to the final visit. The mean number of micturitions per 24 hours in the run-in period was used as the baseline. The secondary efficacy end points were the changes from baseline to the final visit in the mean number of urgency episodes per 24 hours, mean number of urinary incontinence episodes per 24 hours, mean number of urge incontinence episodes per 24 hours, mean volume voided per micturition, and mean number of nocturia episodes. An additional end point was the individual domain scores of the King's Health Questionnaire (KHQ) to assess effects on quality of life (QOL).
Safety assessment
Safety assessments included reporting of AEs, clinical laboratory assessments, vital signs, physical examination, electrocardiogram findings, and measurement of postvoid residual (PVR) volume. An independent cardiovascular adjudication committee determined all deaths and serious potential cardiovascular AEs using the categorization of Antiplatelet Trialists' Collaboration/Major Adverse Cardiovascular Events (APTC/MACE) or non-APTC/MACE.
All unfavorable signs and symptoms observed from the start of the study medication for the run-in period to immediately before administration of the study drug for the treatment period were handled as AEs in the run-in period. Exacerbation of a complication beyond the expected clinical course after initiation of the study medication for the run-in period was included as an AE in the runin period. New AEs developed after administration of the study drug for the treatment period including the post-treatment period. Exacerbation of the symptoms of OAB was not defined as an AE in this clinical study.
Statistical methodology
Efficacy was assessed using the full analysis set (FAS), which included all randomized patients who took at least one dose of the study drug and had at least a baseline and one postbaseline micturition measurement. The domains of the KHQ were evaluated using the QOL analysis set. Safety analyses were performed on the safety analysis set, consisting of all randomized patients who took at least one dose of the study drug. Analysis was performed in these populations based on the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines E3 and E9.
This study was a part of an Asian mirabegron trial conducted in Taiwan, Korea, India, and China. The sample size for the Asian study was reported elsewhere, 26 which was decided with reference to the dose finding study (Study 178-CL-045) conducted in Japan.
Results
Patients' demographic characteristics
A total of 384 patients were screened and 248 patients were randomized into the placebo (n ¼ 81), mirabegron (50 mg; n ¼ 85), and tolterodine SR (4 mg; n ¼ 82) groups. The disposition of patients is shown in Fig. 2 . Of the 248 randomized patients, 218 patients (68 in the placebo, 76 in the mirabegron, and 74 in the tolterodine groups) were included in the FAS. The patient demographics at baseline are presented in Table 1 . In the FAS, no statistically significant imbalance across the three treatment groups was found in any demographic characteristics. The percentage of females ranged from 59.5% to 61.8%. The majority of patients in all treatment groups were aged < 65 years (57.9e67.6%). The mean weights were similar among treatment groups.
Among the patient population, over two thirds had a history of previous drug medication for OAB. No significant difference was noted among the three groups. The mean duration of OAB symptoms was 52.7 months, 48.6 months, and 47.6 months in the placebo, mirabegron, and tolterodine groups, respectively. The majority of the patients in each group took the double-blind study drug for at least 84 days. Table 2 shows the change of efficacy variables from baseline to the final visit. The mean number of micturitions per 24 hours decreased in all treatment groups. The adjusted mean difference between the mirabegron and placebo groups was À1.42, which was statistically significant (p ¼ 0.004). The adjusted mean difference between the mirabegron and tolterodine groups was À1.41. The mirabegron group demonstrated greater reduction in the mean number of micturitions per 24 hours from baseline to the last visit compared with the tolterodine group. No statistically significant difference was found between the tolterodine and placebo groups (p ¼ 0.985).
Efficacy
The mirabegron group demonstrated a statistically significant greater reduction in the mean number of micturitions per 24 hours compared with the placebo group as early as Week 4 (p ¼ 0.017), and efficacy was maintained throughout the treatment period (Weeks 8 and 12; p ¼ 0.050 and p ¼ 0.009, respectively). There was also greater reduction in the mean number of micturitions per 24 hours at Week 12 and at the last visit in the mirabegron group compared with the tolterodine group (Fig. 3) .
The mean changes in the mean volume voided per micturition from baseline to the final visit were 5.54 mL, 22.17 mL, and 13.30 mL in the placebo, mirabegron, and tolterodine groups, respectively. Thus, the mean volume voided per micturition increased in all treatment groups. The adjusted mean difference between the mirabegron and placebo groups was 16.70 mL. The mirabegron (50 mg) group demonstrated a statistically significant greater increase in the mean volume voided per micturition from baseline to the last visit compared with placebo (p ¼ 0.013). The adjusted mean difference between the tolterodine and placebo groups was 7.59 mL (p ¼ 0.258).
In the mirabegron group, an increase in the mean volume voided per micturition was observed at Week 4, and the mean volume voided per micturition subsequently continued to increase until Week 12. Similar changes were also observed in the tolterodine group, but the degree of increase in the mean volume voided per micturition was numerically larger in the mirabegron group compared with the tolterodine group at all time points (Fig. 3) . There was no significant difference between the mirabegron and placebo groups, or between the tolterodine and placebo groups in the mean change from baseline to the final visit in incontinence episodes, urgency episodes, urge incontinence episodes, or nocturia episodes.
KHQ: QOL outcomes
All domain scores for the KHQ decreased from baseline to the last visit in all treatment groups, which indicated improvement of QOL. However, in any domain, no statistically significant difference was found between the mirabegron and placebo groups for changes in the scores from baseline to the last visit. In the mirabegron group, scores for domains of role limitations, physical limitations, emotions, and sleep/energy decreased by > 10 ( Table 3) . 
Safety results
The overall incidence of treatment-emergent AEs (TEAEs) was 42.9% (33/77 patients), 42.4% (36/85), and 49.4% (40/81) in the placebo, mirabegron, and tolterodine groups, respectively. The incidence was lower in the mirabegron group than in the other treatment groups. There was no statistically significant difference in the incidence of TEAEs between the mirabegron group and the other treatment groups. The TEAEs are presented in Table 4 .
The incidence of serious TEAEs including death was one in the placebo group and two serious AEs (SAEs) in the tolterodine group. No drug-related SAE was reported in the mirabegron group. The incidence of TEAEs leading to permanent discontinuation was 1.3%, 2.4%, and 1.2% in the placebo, mirabegron, and tolterodine groups, respectively.
Most TEAEs were mild or moderate in severity in all treatment groups. The most common TEAEs (! 2% of patients) in the mirabegron group were dry mouth (7.1%) and diarrhea (3.5%). The incidence of these events in the mirabegron group was similar to that in the placebo group. In the mirabegron group, the incidence of TEAEs of potential QTc prolongation, hypertension, urinary retention, potential syncope/seizure, potential glaucoma, and potential hepatotoxicity was 0.5%. The incidence of TEAEs of potential cardiac arrhythmia was 3.5%, which was lower than that in the placebo group (9.1%). Changes in laboratory parameters were similar across the treatment groups. No notable change from baseline was found for the mean PVR in any treatment group throughout the treatment period. Fig. 4 shows the changes in the efficacy variables of the mirabegron arm from baseline to the last visit in this study in comparison with those in the mirabegron trials in Japan (Study No. 178-CL-048), 25 the European Union (Study No. 178-CL-046), 22 and the United States (Study No. 178-CL-047). 23 The micturition per 24
Comparison of end points between this study and different mirabegron trials
hours and the mean volume voided showed significant improvement among the four trials. The change of micturition per 24 hours was the greatest in the Taiwanese data compared with the other three trials. Compared with the results of the other three mirabegron trials, the change of incontinence episodes in Taiwanese data was higher than the Japanese trial (À1.37 vs. À1.09); the change of urgency episodes in Taiwanese data was greater than the Japanese and U.S. trials (À1.97 vs. À1.85 vs. À1.57, respectively); urge incontinence episodes in Taiwanese data were higher than the Japanese, European, and U.S. trials (À1.73 vs. À0.98 vs. À1.33 vs. À1.32, respectively); the mean volume voided in the Taiwanese data was higher than in the U.S. trial (22.2 vs. 18.4); and the nocturia episode was higher than in the Japanese trial (À0.54 vs. À0.45). However, in these parameters, mirabegron did not show superior effect to placebo as shown in the other three trials. Nevertheless, the safety profile of mirabegron in this trial was as good as that in the other three trials.
Discussion
The results of this study confirmed that mirabegron (50 mg) is safe and effective in decreasing micturition frequency and increasing the volume voided in Taiwanese people with OAB during a 12-week treatment period.
Recently, three international phase III randomized controlled trials of mirabegron have demonstrated statistically significant improvements in the decrease of episodes of frequency urgency and urge incontinence compared with placebo.
23e25 A pooled analysis of these studies showed that mirabegron is well tolerated and has a good safety profile in patients with OAB. 21 In a 12-month safety and efficacy study, mirabegron was demonstrated to improve key OAB symptoms from the first measured time point of 4 weeks, and the efficacy was maintained throughout the 12-month treatment period. 24 In addition, patients treated with mirabegron showed statistically significant improvements in health-related QOL measures versus placebo. The magnitude of the treatment response is similar to that of other OAB agents. 27 In this study, mirabegron (50 mg) showed statistically significant superiority to placebo with regard to the change in mean number of micturition per 24 hours from baseline to the last visit in Taiwanese patients. Mirabegron (50 mg) also showed statistically significant superiority to placebo in the change of mean volume voided per micturition from baseline to the last visit. These results were similar to those in trials of other regions such as Japan, the European Union, and the United States. Although mirabegron (50 mg) did not show statistically significant superiority to placebo in the change of mean number of urgency, urge incontinence, or nocturia episodes, the changes of these variables in the mirabegron arm were similar with those in other regional trials.
Although the change in QOL measurements after mirabegron treatment did not show statistically significant superiority to placebo in all domain scores of QOL as assessed by the KHQ, all domain scores were decreased after the treatment, which indicates that a subjective improvement was experienced in Taiwanese patients treated with mirabegron (50 mg). Moreover, the incidence of most common TEAEs was similar to those in other regional trials, which confirmed the safety of mirabegron in OAB treatment.
It is difficult to explain why mirabegron (50 mg) shows the efficacy only in reduction of daily frequency and increased volume voided in Taiwanese people as well as in other regional trials, but the placebo effect in the placebo arm was too high to result in a significant difference in other efficacy end points between mirabegron and placebo. The most likely reason is the small case number in this trial. Because the data are extracted from the Asian trial, the case number of Taiwanese data might not be sufficient for a statistical significance. It is also noteworthy that tolterodine (4 mg) did not show any significant difference to placebo in any efficacy variable. These results suggest that mirabegron has the therapeutic efficacy in treatment of OAB in Taiwanese people.
The placebo effect in this study is higher than that in the trials of other regions. 23e25 The reasons for the high placebo effect could be including patients with a low urgency grade and high percentage of patients having received antimuscarinic medication. In this trial, we did not define OAB with a higher urgency grade (G3 or G4 in the European Union and U.S. trials). Urgency should be the primary or coprimary end point for future studies of OAB and detrusor overactivity. 28 However, younger patients and OAB dry patients might have a higher incidence of bladder oversensitivity rather than detrusor overactivity. Our previous study had shown that a higher urgency severity score recorded in conjunction with a voiding diary and wet OAB was strongly associated with urodynamic detrusor overactivity. 29 It is possible that a considerably high percentage of patients enrolled in this Taiwanese trial might not have true OAB. In that case, the placebo effect increases. It should be noted that, as seen in other studies of antimuscarinic agents, the placebo effect is usually high in OAB clinical trials. 30 In this study, > 75% of patients had received medication for OAB previously. The high placebo effect might be due to specific characteristics of Taiwanese people who have high expectations for the new test drug after failed treatments with previous agents. This high placebo response diminished the treatment effect seen with mirabegron in this Taiwanese data. It is also interesting to note that there is a poor tolterodine effect in this Taiwanese data. None of the primary or secondary variables were found to have significantly superior effect to placebo in the tolterodine arm. As stated earlier, in this study > 75% of patients received drug medication for OAB previously, mainly antimuscarinic agents. It is not surprising that most patients who agreed to participate in this mirabegron trial experienced treatment failures with antimuscarinics, and therefore, did not show response to the active treatment drug tolterodine.
Conclusion
Based on the results of this study conducted in Taiwan, it is concluded that mirabegron at a dose of 50 mg once daily for 12 weeks is superior to placebo in reducing the frequency of micturitions and increasing the volume voided in patients with symptoms of OAB. Mirabegron at a dose of 50 mg once daily for 12 weeks was safe and well tolerated. No clinically relevant AEs were identified in patients with symptoms of OAB.
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